Boots Sale Explored
Sycamore Partners Considers £7.5 Billion Boots Sale, Abandoning Prior London IPO Plans
Anonymous
Key Points
1
After Sycamore’s takeover of Walgreens Boots Alliance, the deal led to major restructuring: Walgreens, Boots, Shields Health Solutions, CareCentrix and VillageMD were repositioned as standalone companies, and Walgreens Boots Alliance was delisted from Nasdaq—its investors received “USD11.45 per share in cash” plus a potential “up to an additional USD3.00 per share” tied to future VillageMD proceeds.
2
Sigma Healthcare publicly walked a careful line on the sale: it acknowledged “recent media speculation” and said it “continuously reviews opportunities that would create value for shareholders” and had “engaged in preliminary discussions in relation to the sale process,” adding “There is no certainty that any transaction will eventuate.”
3
Boots’ recent operating performance is being positioned as part of the backdrop to the decision over a sale versus listing: CityAM reported pre-tax profit jumped 25% to £337m in the year to August, and retail sales rose nearly 6% as the company approached its private takeover.
4
The potential IPO was also framed as important for the London Stock Exchange beyond Boots itself: CityAM said the float would give a “major boost” as policymakers try “to end a recent drought of listings” by loosening “tax and regulation.”
Sycamore Partners is reportedly shelving plans to float Boots on the London Stock Exchange, instead pursuing a private sale valuing the pharmacy chain at around £7.5 billion ($10 billion), according to The Financial Times. Talks have begun with two main bidders: the Weston family's investment arm Wittington Investments, which also owns Shoppers Drug Mart in Canada, and Australian pharmacy group Sigma Healthcare.
Sigma Healthcare confirmed it had "engaged in preliminary discussions in relation to the sale process" in an ASX filing, but added there is "no certainty that any transaction will eventuate." City AM reported Boots posted a 25% jump in pre-tax profit to £337 million in the year to August 2025, making it a more attractive target than it was just two years ago.
How Sycamore Broke Up Walgreens Boots Alliance
Sycamore Partners took Walgreens Boots Alliance (WBA) private in August 2025 in a deal worth up to $23.7 billion. WBA shareholders received $11.45 per share in cash, plus a potential extra $3.00 per share tied to future proceeds from VillageMD, according to The Grocer. The Nasdaq-listed parent was then delisted entirely.
Sycamore immediately split WBA into five standalone businesses: Walgreens, The Boots Group, Shields Health Solutions, CareCentrix, and VillageMD. The break-up freed Boots from the struggling US healthcare operations that had weighed on WBA for years. A trade sale of Boots within a year of the acquisition would mark a rapid exit from a major piece of that restructuring, Nottingham Post noted.
Who Wants to Buy Boots and What They're Offering
The Weston family is bidding through Wittington Investments. The Canadian billionaire dynasty already runs Loblaw, Canada's largest grocer, and Shoppers Drug Mart, one of its biggest pharmacy chains. Adding Boots would give them a major foothold on the British high street. The family has declined to comment, according to The Financial Times.
Sigma Healthcare is the other named bidder. The Australian-listed firm entered the UK market in May 2026 through a joint venture with Greenlight Healthcare. Sigma shares fell roughly 5% in Sydney after the talks became public, as investors worried about the cost and complexity of buying a chain with around 1,800 UK stores, according to Guru Focus.
Why Sycamore Dropped the London IPO Plan
As recently as April 2026, Sycamore was preparing to list Boots in London at a valuation of around £7 billion. The appointment of Alex Baldock — former CEO of FTSE-listed Currys — as Boots CEO-elect was widely seen as a sign an IPO was coming. A private sale at £7.5 billion, however, offers a faster and more certain payout, Pharmacy Magazine reported.
Boots' recent performance made it attractive to both routes. Revenue reached £7.5 billion in the year to August 2025, up 3.2%. Online sales at Boots.com rose 18.3%. The company also launched 180 new "beauty hall" concepts in stores and expanded sales of GLP-1 weight-loss treatments, strengthening its retail appeal, according to City AM.
A Fresh Blow to London's Struggle to Attract Listings
A Boots IPO had been described as a potential "major boost" for the London Stock Exchange, which has suffered a drought of new listings in recent years. UK policymakers have been loosening tax and regulatory rules to lure companies back to London's public markets. If Boots sells to a foreign trade buyer instead, that opportunity disappears, City AM warned.
This is not the first time Boots has escaped a London listing. Walgreens explored a Boots sale in 2022 but abandoned it after bidders — including Reliance Industries and Apollo Global Management — failed to meet the asking price as interest rates rose. For Boots' roughly 6,000 employees at its Beeston headquarters in Nottinghamshire, the identity of the next owner remains an open question, Nottingham Post noted.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
29
Reach
40
A
AnonymousAuthor
